2 recruiting. 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Recruiting 2 |
Follow Phase 1b: new trials by email Literature Review of Phase 1b trials Research Report on Phase 1b
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 1b, Open-Label Study Of REC-617, A Selective CDK7 Inhibitor, In Patients With Metastatic Or Unresectable RB1-Negative Leiomyosarcoma After Prior Systemic Therapy REC617 - Phase 1b, Open Label | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 15 | 2026-10-19 | 2026-07-31 |
| A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK) Nivolumab, HC-7366, ipilimumab - Phase 1b, HC-7366 | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 35 | 2026-03-24 | 2026-09-25 |
Kidney Neoplasms (1) · Leiomyosarcoma (1)
Neoplasms (2) · Female Urogenital Diseases (1) · Female Urogenital Diseases and Pregnancy Complications (1) · Kidney Diseases (1) · Male Urogenital Diseases (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Neoplasms, Connective and Soft Tissue (1) · Neoplasms, Muscle Tissue (1) · Sarcoma (1) · Urogenital Diseases (1) · Urogenital Neoplasms (1) · Urologic Diseases (1) · Urologic Neoplasms (1)
Ipilimumab (1) · Nivolumab (1)
M.D. Anderson Cancer Center (2)
United States (2)
Elise Nassif, MD (1) · Eric Jonasch, MD (1)